Company: VCYT
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001384101-25-000060
Chunk: 72

Company: VERACYTE, INC.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 8
Chunk 72
---
 business activities, nor is there any intent to bifurcate the overall business review process to produce discreet operating results specific to any of the Company's business activities. The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets. Consolidated revenue does not include any inter-segment sales or transfers.

16

Information about reported segment revenue, measures of segment profit or loss, significant segment expenses and reconciliation to income from operations was as follows (in thousands):Three Months Ended March 31,March 31, 2025March 31, 2024Revenue:Testing revenue$107,309 $90,303 Product revenue3,580 3,537 Biopharmaceutical and other revenue3,584 3,004 Total revenue114,473 96,844 Cost of revenue:Cost of testing revenue:Laboratory supplies and reagents expense13,067 11,918 Sample collection expense2,825 3,057 Compensation expense5,611 5,215 Other cost of testing revenue (1)3,385 2,846 Allocation of facilities and IT expenses3,372 2,943 Total cost of testing revenue28,260 25,979 Cost of product revenue:Product costs109 1,263 License fees and royalties324 436 Other cost of product revenue (2)792 824 Allocation of facilities and IT expenses197 121 Total cost of product revenue1,422 2,644 Cost of biopharmaceutical and other revenue:Compensation expense1,240 1,462 Other cost of biopharmaceutical and other revenue (3)1,044 949 Allocation of facilities and IT expenses414 427 Total cost of biopharmaceutical and other revenue2,698 2,838 Intangible asset amortization - cost of revenue2,585 2,915 Gross profit79,508 62,468 Operating expenses:Research and development:Compensation expense9,748 9,085 Direct research and development expense4,141 3,874 Other research and development expenses (4)1,815 1,519 Allocation of facilities and IT expenses2,016 1,487 Total research and development17,720 15,965 Selling and marketing:Compensation expense17,635 17,622 Direct marketing expense710 1,138 Other selling and marketing expenses (5)3